Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies
This study aimed to prospectively evaluate the utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/magnetic resonance (MR) combined with gadoxetate disodium in patients with clinical suspected hepatic malignancies (lesion diameter ≤ 3.0cm), with histopathological findings obtained from biopsy or resected surgical specimens, or follow-up results as reference standards.
- EligibilityCriteria: Inclusion Criteria:  Patient ≥ 18 years of age at the time of consent; Patients with suspected, newly diagnosed, or previously treated liver cancer; Estimated creatinine clearance > 30ml/min; Provided written informed consent authorisation before participating in the study.  Exclusion Criteria:  Allergic to the gadoxetate disodium； MRI contraindications, not limited to cardiac implantable electronic devices and claustrophobia; Weight > 90Kg; Pregnancy or lactation; Active inflammation may affect FAPI imaging. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The subjects the investigators selected are adults who are not restricted by gender. - SamplingMethod: Probability Sample